SCHEMBL7914700

SCHEMBL7914700

[CH2]C(O)CC(=O)OCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3066350 0.83
SCHEMBL1258369 0.80 GAA (0.55)
SCHEMBL16558808 0.80 MGAM (0.55)
SCHEMBL3787925 0.80
SCHEMBL272457 0.79 MGAM (0.48)
Formaldehyde SCHEMBL5845336 0.79 MGAM (0.48)
SCHEMBL7859418 0.79 GAA (0.48)
SCHEMBL76382 0.78
SCHEMBL54111 0.78
SCHEMBL434191 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100453530-C Compound for inhibiting VCAM-1 expression and pharmaceutical composition thereof ATHEROGENICS INC (US) 2009-01-21 CN claimed
CN-101284808-A Compounds and methods for the inhibition of the expression of VCAM-1 ATHEROGENICS INC (US) 2008-10-15 CN claimed
CN-1263522-A Compounds and methods for inhibiting VCAM-1 expression ATHEROGENICS INC (US) 2000-08-16 CN claimed
CN-101686676-A Methods and compositions of derivatives of probucol for the treatment of diabetes ATHEROGENICS INC 2010-03-31 CN disclosed
CN-100453530-C Compound for inhibiting VCAM-1 expression and pharmaceutical composition thereof ATHEROGENICS INC (US) 2009-01-21 CN disclosed
CN-101284808-A Compounds and methods for the inhibition of the expression of VCAM-1 ATHEROGENICS INC (US) 2008-10-15 CN disclosed
CN-100401400-C Rewritable optical information recording medium and recording/reproducing method, recording/reproducing device SONY CORP MITSUI CHEMICALS INC (JP) 2008-07-09 CN disclosed
CN-100384943-C The use of aromatic compounds as phase directors and particle size reducers for quinacridone pigments CIBA SC HOLDING AG (CH) 2008-04-30 CN disclosed
CN-1311988-C Imide compounds and optical recording media made by using the same MITSUI CHEMICALS INC (JP) 2007-04-25 CN disclosed
CN-1867980-A Optical recording medium and compound for use in the same MITSUI CHEMICALS INC (JP) 2006-11-22 CN disclosed
CN-1224524-C Benzodiazolyl compound, and compound for optical recording medium MITSUI CHEMICALS INC (JP) 2005-10-26 CN disclosed
CN-1575236-A Imide compounds and optical recording media made by using the same MITSUI CHEMICALS INC OGISO AKI (JP) 2005-02-02 CN disclosed
CN-1501964-A The use of aromatic compounds as phase directors and particle size reducers for quinacridone pigments �������⻯ѧƷ�ع����޹�˾ 2004-06-02 CN disclosed
CN-1434771-A Optical recording medium and azaporphyrin compound MITSUI CHEMICALS INC (JP) 2003-08-06 CN disclosed
CN-1406182-A Benzodiazolyl compound, optical recording medium compound MITSUI CHEMICALS INC (JP) 2003-03-26 CN disclosed
CN-1338738-A Optical recording media and porphinoid compound MITSUI CHEMICALS INC (JP) 2002-03-06 CN disclosed
US-6248161-B1 Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts HEWLETT-PACKARD COMPANY 2001-06-19 US disclosed
CN-1263522-A Compounds and methods for inhibiting VCAM-1 expression ATHEROGENICS INC (US) 2000-08-16 CN disclosed
CN-1133859-A Stabilizer combination CIBA GEIGY AG (CH) 1996-10-23 CN disclosed
CN-1091288-A The oxytocin antagonist OTSUKA PHARMA CO LTD (JP) 1994-08-31 CN disclosed